Quick Answer
Tempest Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2024.
Tempest Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $0.00 | -100.0% |
| 2023 | $6.26M | -39.6% |
| 2022 | $10.37M | -31.2% |
| 2021 | $15.07M | +24603.3% |
| 2020 | $61.0K | -63.7% |
| 2019 | $168.0K | -56.1% |
| 2018 | $383.0K | -36.1% |
| 2017 | $599.0K | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | -100.0% | -100.0% |
| June 30, 2024 | $2.01M | -73.2% | -51.5% |
| March 31, 2024 | $4.14M | -53.7% | -33.9% |
| December 31, 2023 | $6.26M | -39.6% | -25.2% |
| September 30, 2023 | $8.37M | -29.3% | +11.9% |
| June 30, 2023 | $7.48M | -43.7% | -16.2% |
| March 31, 2023 | $8.94M | -41.0% | -13.8% |
| December 31, 2022 | $10.37M | -31.2% | -12.4% |
- Tempest Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2017–2024 period, Tempest Therapeutics, Inc.’s long-term debt has declined by 100.0% (from $599.0 thousand to $0.00).
- The most recent figure is from Tempest Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: